ISS, 13 maggio 2021 -
In relation to press reports on a clinical trial on a potential vaccine model providing long-term coverage against SARS-Cov2 being carried out at the Istituto Superiore di Sanità - ISS (Italian National Institute of Health), the following is specified:
This model, which involves animal models, is currently in the preclinical study phase which has not been completed yet.
The research has not been put on hold but is following the normal consolidation procedure as for all other potential vaccine models.
The possible long duration of vaccination coverage is obviously not yet supported by scientific evidence but is based on data from the literature and in the course of its development, we do not rule out the need for integration with current vaccine technologies (mRNA vaccines). Furthermore, the current phase does not allow for a quantitative estimate to be made of the effectiveness and actual duration of vaccination coverage.
The technology of the ISS vaccine, currently under study, is based on the activation of immunity induced by CD8 T cells. It is original compared to the technology of the other vaccines in use and further possible developments are being studied.
In recognizing the potential of this research, the Institute has systematically supported the requests for funding required for its development and has also deemed it appropriate to protect it by filing an additional patent application to possibly guarantee its use for the protection of public health.
